TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07887971: A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

Sponsor: Aktis Oncology, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 152 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07887971 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07887971 Rescue Dossier →